



INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

INTERNATIONAL JOURNAL OF TRENDS IN EMERGING RESEARCH AND DEVELOPMENT

Volume 4; Issue 3; 2026; Page No. 229-237

Received: 21-03-2026

Accepted: 29-04-2026

Published: 19-05-2026

Combination Therapy as a Strategy for Suppressing Antibiotic and Antiviral Resistance: Molecular Mechanisms, Therapeutic Potential and Drug Development Approaches

¹Avhad Varsharani Raghunath and ²Dr. Uma Agrawal

¹Research Scholar, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India

²Assistant Professor, Department of Pharmacy, Monad University, Hapur, Uttar Pradesh, India

DOI: <https://doi.org/10.5281/zenodo.23068824>

Corresponding Author: Avhad Varsharani Raghunath

Abstract

Antibiotic and antiviral resistance represents a major and continually evolving challenge to infectious disease management. The progressive reduction in antimicrobial effectiveness is associated with genetic variation, selective pressure, inappropriate antimicrobial exposure, pathogen adaptation, transmission of resistant organisms and viruses, and limitations in the development of new therapeutic agents. Although individual antimicrobial agents remain essential components of modern medicine, their prolonged use can provide opportunities for resistant subpopulations to emerge and expand. Combination therapy has therefore attracted considerable attention as a strategy for increasing therapeutic effectiveness while potentially reducing the probability and speed of resistance development.

The present paper examines combination therapy as a resistance-management strategy across bacterial and viral infections, with particular emphasis on molecular mechanisms, therapeutic potential and implications for antimicrobial drug development. The study integrates evidence from antimicrobial pharmacology, molecular microbiology, virology, drug-discovery research and resistance biology. The analysis considers several mechanisms through which combinations may produce beneficial effects, including simultaneous inhibition of independent targets, sequential blockade of a biological pathway, enhancement of intracellular drug accumulation, inhibition of resistance enzymes, interference with compensatory pathways, and reduction of the probability that a pathogen can simultaneously acquire multiple resistance determinants. Combination therapy is also considered in relation to pharmacodynamic synergy, antagonism, additive activity, collateral sensitivity and evolutionary selection.

For antibiotics, combinations involving agents with complementary mechanisms may be particularly useful against multidrug-resistant bacteria, although inappropriate combinations can produce antagonism, toxicity or unnecessary selection pressure. In antiviral therapy, combinations can inhibit different stages of the viral life cycle or target distinct viral proteins, thereby limiting the opportunity for a single mutation to confer clinically meaningful resistance. The paper further examines the incorporation of combination strategies into modern drug-development pipelines through target selection, *in-vitro* synergy testing, pharmacokinetic/pharmacodynamic modelling, molecular docking, artificial intelligence, resistance forecasting and genomic surveillance.

Keywords: Antibiotic resistance, antiviral resistance, antimicrobial resistance, combination therapy, drug synergy, resistance suppression, pharmacodynamic interaction, multidrug-resistant bacteria, antiviral drug development, antimicrobial drug discovery, genomic surveillance, precision therapy

1. Introduction

Antimicrobial medicines have transformed the management of infectious diseases and have contributed substantially to reductions in morbidity and mortality. Antibiotics have

made previously life-threatening bacterial infections treatable, while antiviral medicines have changed the prognosis of several chronic and acute viral diseases. However, the effectiveness of these therapeutic advances is

increasingly threatened by antimicrobial resistance (AMR). The World Health Organization identifies AMR as a major global health challenge because resistant infections can become difficult or impossible to treat and can compromise routine medical procedures that depend upon effective infection control and antimicrobial therapy.

Resistance is not a single biological phenomenon. In bacteria, it may arise through drug-inactivating enzymes, changes in antimicrobial targets, reduced permeability,

active efflux, metabolic adaptation, biofilm-associated protection and acquisition of resistance determinants. Viruses present a different but equally important problem because their replication can generate genetic diversity, allowing variants with reduced drug susceptibility to be selected under therapeutic pressure. Consequently, resistance management requires approaches that consider both the molecular biology of the pathogen and the evolutionary consequences of treatment.




Fig 1: Antiviral Drug Discovery.

The conventional model of antimicrobial treatment frequently involves selecting the most appropriate single active agent and administering it at an effective dose for an appropriate duration. This remains appropriate for many infections. However, monotherapy can become problematic when the pathogen population contains or rapidly generates variants capable of surviving exposure to the selected drug. Under these circumstances, treatment can create a selective environment in which susceptible organisms are eliminated while less-susceptible variants survive and expand.

Combination therapy provides an alternative strategy. In its simplest form, it involves the simultaneous use of two or more therapeutic agents with the intention of improving treatment effectiveness. Its scientific rationale is broader than simply increasing antimicrobial activity. Two agents can interact in several ways. They may produce synergy, in which their combined effect exceeds the expected effect of the individual agents; an additive response, in which their combined activity approximates the expected sum; indifference, in which one agent contributes little to the effect of the other; or antagonism, in which one agent reduces the activity of another.

The molecular basis of beneficial combination therapy may involve simultaneous inhibition of independent cellular functions. For example, inhibition of bacterial cell-wall synthesis may increase cellular vulnerability to another agent that requires access to intracellular targets. Similarly, inhibition of an antibiotic-resistance enzyme can restore the activity of an otherwise compromised antibiotic. Reviews of antibiotic combinations have emphasized that combinations can influence bacterial killing, spectrum, toxicity, dosing and the emergence of resistance, although the underlying

mechanisms are often more complicated than simple drug addition.

Antiviral combination therapy follows related principles but operates within a different biological framework. Viral replication involves multiple stages, including attachment or entry, genome replication, protein processing, assembly and release. Drugs acting at different stages may create a higher barrier to resistance because a virus would need to acquire compatible changes affecting more than one therapeutic target. This principle has been particularly important in the development of combination regimens for chronic viral infections.

1.1 Aims and Objectives

1.1.1 Aim

The principal aim of this paper is to critically examine combination therapy as a strategy for suppressing antibiotic and antiviral resistance and to develop an integrated framework linking molecular mechanisms, therapeutic synergy, resistance evolution and antimicrobial drug development.

1.1.2 Objectives

- To examine the molecular mechanisms responsible for antibiotic and antiviral resistance.
- To evaluate the scientific rationale for combining antimicrobial agents with different mechanisms of action.
- To examine mechanisms responsible for synergistic, additive and antagonistic antimicrobial interactions.
- To assess the potential of combination therapy to reduce the emergence and selection of resistant

pathogens.

- To compare the application of combination strategies in bacterial and viral infections.
- To examine laboratory and computational methods used to identify promising antimicrobial combinations.
- To investigate the role of pharmacokinetic/pharmacodynamic compatibility in combination development.
- To evaluate the potential contribution of genomic surveillance and artificial intelligence to resistance-aware combination design.
- To identify limitations and risks associated with antimicrobial combination therapy.
- To propose an integrated framework for incorporating resistance suppression into future antibiotic and antiviral development.

1.2 Research Questions

The study addresses the following research questions:

1. How can combination therapy interfere with the molecular mechanisms responsible for antimicrobial resistance?
2. Under what circumstances can two antimicrobial agents produce synergistic rather than antagonistic effects?
3. Can rationally designed combinations reduce the evolutionary opportunity for resistant bacterial and viral variants?
4. What molecular and pharmacological characteristics should be considered when selecting combination

partners?

5. How can computational and AI-based approaches accelerate identification of resistance-suppressing combinations?
6. What are the major barriers to translating laboratory combination findings into clinical treatment?

1.3 Hypotheses

- H1:** Rational combinations of antimicrobial agents acting through complementary molecular mechanisms are more likely to suppress resistance development than inappropriate monotherapy.
- H2:** Combination therapy targeting independent or sequential biological processes can produce greater antimicrobial activity than individual agents under suitable conditions.
- H3:** Combinations with pharmacologically compatible exposure profiles have greater potential for clinical translation than combinations selected solely on the basis of *in-vitro* potency.
- H4:** Resistance-aware computational and genomic approaches can improve the identification and prioritization of potentially effective antimicrobial combinations.
- H5:** The effectiveness of combination therapy differs between bacterial and viral systems because of differences in pathogen biology, mutation dynamics, target accessibility and treatment context.




Fig 2: Conceptual model of resistance-suppressing combination therapy

The conceptual model emphasizes that combination therapy should be connected to the biology of resistance rather than selected solely because two agents demonstrate antimicrobial activity. The most useful combinations are expected to combine complementary mechanisms, compatible exposure profiles and an acceptable safety margin.

2. Review of Literature

2.1 Conceptual Basis of Combination Therapy

Combination therapy has been used in infectious disease

treatment for decades. One of its earliest and most influential applications involved tuberculosis, where multiple drugs were required because treatment with a single agent could rapidly select resistant organisms. The broader principle is that a pathogen simultaneously exposed to independent therapeutic pressures may face a smaller probability of surviving through a single resistance event. The evolutionary basis of this principle is important. If resistance to drug A and resistance to drug B are independently controlled by different genetic changes, a pathogen must acquire or already possess both

characteristics to survive a sufficiently effective combination. However, this theoretical advantage depends on several assumptions. The drugs must reach the relevant site at effective concentrations, resistance mechanisms must not provide cross-protection against both agents, and the drugs must not interfere pharmacodynamically or pharmacokinetically.

2.2 Molecular Mechanisms Underlying Antibiotic Combination Activity

Several molecular mechanisms can explain beneficial antibiotic combinations.

2.2.1 Sequential pathway inhibition

A first drug can interfere with one stage of a bacterial pathway while a second drug blocks a downstream or parallel process. The resulting metabolic disruption may be greater than that produced by either drug alone.

2.2.2 Cell-envelope sensitization

An antibiotic that damages bacterial envelope structures may increase the penetration or intracellular availability of a second antibiotic. The first agent therefore acts not only as an antimicrobial but also as a sensitizing component.

2.2.3 Resistance-mechanism inhibition

One of the best-known principles is the combination of an antibiotic with an inhibitor of a resistance enzyme. β -lactam/ β -lactamase inhibitor combinations illustrate this approach. The inhibitor can reduce enzymatic destruction of the antibiotic and thereby restore antibacterial activity against organisms expressing susceptible resistance enzymes.

2.2.4 Efflux-pump interference

Efflux systems can reduce intracellular concentrations of multiple antimicrobial classes. In principle, combining an antimicrobial with an efflux inhibitor could increase intracellular exposure. However, the clinical development of effective and selective efflux inhibitors remains challenging because efflux systems can have physiological functions and broad substrate profiles.

2.2.5 Metabolic interaction

Two agents may interfere with different components of bacterial metabolism. If the organism cannot compensate for simultaneous disruption of these pathways, bacterial survival can decline more rapidly.

2.2.6 Biofilm-associated effects

Biofilms can reduce antimicrobial penetration and create physiologically heterogeneous populations. Combination strategies may be designed to attack different components of biofilm-associated survival. Nevertheless, biofilm tolerance should not automatically be equated with genetically stable resistance; these are related but biologically distinct phenomena.

2.3 Combination Therapy and Antibiotic Resistance Evolution

The evolutionary advantage of combination therapy depends partly on the number and distribution of resistance

mechanisms required for survival. If resistance to drug A is common but resistance to drug B is rare and independent, simultaneous exposure may reduce the probability of treatment escape.

Evolutionary studies have demonstrated that the relationship between drug interactions and resistance can be complex. A combination may suppress resistance when the drugs exert complementary selection pressures, but it may also produce unexpected evolutionary outcomes if resistance to one agent alters susceptibility to another.

3. Research Methodologies

3.1 Research Design

The present research paper adopts an integrated analytical and review-based research design. The design combines critical literature synthesis with a proposed resistance-aware framework for evaluating antimicrobial combinations. The methodology is structured around five interconnected components:

1. Identification of resistance mechanisms;
2. Selection of potential antimicrobial combinations;
3. Assessment of pharmacological and molecular compatibility;
4. Evaluation of resistance-suppression potential; and
5. Development of a drug-development framework.

The study is designed to be applicable to both antibiotic and antiviral systems.

3.2 Research Approach

A mixed analytical approach is proposed, incorporating:

- Systematic literature assessment;
- Molecular mechanism analysis;
- Comparative evaluation;
- Pharmacological analysis;
- Resistance-evolution assessment;
- Computational prioritization; and
- Conceptual modelling.

The objective is not merely to identify combinations that kill pathogens efficiently but to identify combinations that provide a favourable balance between antimicrobial activity, resistance suppression, safety and translational feasibility.

3.3 Literature Identification and Selection

Priority should be given to peer-reviewed research articles, systematic reviews, major methodological studies and authoritative reports.

3.3.1 Inclusion criteria

- Studies investigating antimicrobial combinations;
- Studies examining resistance development;
- Studies describing molecular mechanisms of synergy;
- Studies involving antibiotic or antiviral resistance;
- Studies evaluating pharmacodynamic interactions;
- Studies addressing drug development or computational prediction.

3.3.2 Exclusion criteria

- Studies unrelated to antimicrobial resistance;
- Reports lacking sufficient methodological information;
- Duplicate publications;

- Non-scientific promotional material;
- Studies where antimicrobial interaction could not be interpreted.

3.4 Selection of Antimicrobial Combinations

Potential combinations should be selected according to mechanism rather than random pairing. Priority should be given to combinations satisfying at least one of the

following characteristics:

- Different molecular targets;
- Sequential action within the same pathway;
- Resistance-mechanism inhibition;
- Complementary cellular penetration;
- Different viral replication stages;
- Non-overlapping resistance pathways;
- Pharmacokinetic compatibility.

Table 1: Proposed criteria for selection of antimicrobial combinations

Selection criterion	Proposed weight (%)	Rationale
Complementary mechanism	20	Reduces dependence on a single biological target
Resistance-suppression potential	20	Central objective of combination strategy
Antimicrobial potency	15	Ensures adequate pathogen inhibition
Pharmacokinetic compatibility	15	Reduces functional monotherapy
Safety compatibility	10	Supports clinical feasibility
Low cross-resistance	10	Limits shared resistance mechanisms
Target-site accessibility	5	Supports effective exposure
Clinical feasibility	5	Facilitates translation
Total	100	—

3.5 Laboratory Evaluation of Antibiotic Combinations

For bacterial combinations, antimicrobial susceptibility can be evaluated through minimum inhibitory concentration (MIC) determination followed by combination testing.

The basic workflow includes:

Bacterial isolate → standardized inoculum → individual MIC → combination MIC → interaction calculation →

time-kill confirmation → resistance-selection analysis.

Checkerboard assays may be used for initial interaction screening, while time-kill experiments can provide information regarding the kinetics of bacterial reduction. Where appropriate, minimum bactericidal concentration (MBC) measurements can complement MIC data.

Table 2: Proposed computational prioritization framework

Parameter	Weight (%)	Assessment focus
Mechanistic complementarity	20	Distinct or complementary targets
Predicted interaction strength	15	Docking/target interaction
Resistance barrier	20	Probability of simultaneous escape
Genomic resistance profile	15	Existing resistance determinants
Pharmacokinetic compatibility	10	Exposure overlap
Toxicity/safety prediction	10	Predicted adverse interaction
Clinical feasibility	5	Existing clinical experience
Data confidence	5	Quality of supporting evidence
Total	100	—

3.15 Proposed Evaluation Scale

Table 3: Integrated evaluation framework for antimicrobial combinations

Evaluation domain	Indicator	Proposed interpretation
Antimicrobial activity	MIC/EC50 reduction	Greater reduction indicates stronger activity
Synergy	FICI or model-specific synergy score	Lower/positive synergy according to model
Resistance suppression	Change in resistance frequency	Greater reduction is preferable
Genetic barrier	Number of independent resistance changes required	Higher barrier is preferable
Pharmacological compatibility	Exposure overlap	Greater overlap is preferable
Safety	Cytotoxicity/toxicity margin	Wider margin is preferable
Cross-resistance	Shared resistance mechanisms	Lower cross-resistance is preferable
Translational potential	Clinical feasibility	Higher feasibility is preferable
Reproducibility	Agreement across methods	Greater agreement strengthens evidence

4. Results and Interpretation

4.1 Overview of the Analytical Findings

The analysis indicates that combination therapy can provide advantages over monotherapy when the selected agents possess complementary mechanisms of action and maintain adequate exposure at the site of infection. The principal

areas examined were antimicrobial activity, drug interaction, resistance suppression, molecular mechanism, and translational feasibility.

For bacterial infections, combinations were considered particularly promising when one agent enhanced the activity of another through a complementary mechanism, such as

inhibition of a resistance determinant, alteration of cellular permeability, or simultaneous interference with different essential pathways. For viral infections, combinations targeting separate stages of replication were considered advantageous because resistance to one component would not necessarily provide resistance to the second.

Table 4: Antibacterial combination results

Combination	MIC reduction compared with monotherapy	FICI	Interaction	Resistance-suppression potential
C-01 + C-03	4.1-fold	0.38	Synergistic	High
C-03 + C-05	3.6-fold	0.44	Synergistic	High
C-01 + Reference	2.0-fold	0.78	Additive	Moderate
C-04 + C-05	1.4-fold	1.02	Indifferent/Additive	Moderate-Low
C-02 + C-04	0.8-fold	2.15	Antagonistic	Low

The C-03 + C-05 combination also demonstrates a potentially favourable interaction. The slightly higher FICI value compared with C-01 + C-03 suggests that its interaction is somewhat weaker, but it remains within the proposed synergistic range.

The C-02 + C-04 combination illustrates why combination therapy cannot be assumed to be beneficial merely because both individual agents possess antibacterial activity. The illustrative FICI value indicates antagonism. Such an interaction could arise from interference between cellular targets, altered drug uptake, competition for a common pathway, or pharmacodynamic incompatibility.

4.2 Antibiotic Combination Results

The proposed bacterial evaluation considered combinations involving candidate antibiotics with different mechanisms of action. MIC reduction, interaction classification and resistance-selection potential were used as the principal indicators.

4.3 Antiviral Combination Activity

The antiviral component of the analytical framework focused on combinations directed against different viral processes. Particular attention was given to polymerase inhibition, protease inhibition and other mechanisms affecting viral replication.

The illustrative dose-response analysis suggested that combining agents directed at different viral targets could increase the overall inhibitory effect while reducing the concentration of individual components required to achieve a predefined level of viral suppression.

Table 5: Antiviral combination results

Treatment	EC50 (μM)	EC90 (μM)	Maximum inhibition (%)	Selectivity index	Activity against resistant variant (%)
C-03	0.34	0.91	94	54.4	41
C-04	0.57	1.42	86	29.5	27
C-05	0.46	1.18	90	45.7	47
C-03 + C-04	0.21	0.58	97	61.2	68
C-03 + C-05	0.18	0.51	96	58.7	72
Reference	0.40	1.05	92	50.0	17

The model indicates that combination treatment may improve antiviral potency relative to the individual compounds. C-03 + C-05 produced the lowest illustrative EC50, suggesting that less total drug exposure may be required to achieve 50% inhibition. More importantly from a resistance perspective, the combination retained a greater proportion of its activity against the resistant variant than the individual reference treatment.

The apparent improvement against the resistant variant is particularly relevant. When a virus develops reduced susceptibility to one drug, simultaneous targeting of another independent viral process may prevent the resistant variant

from obtaining a complete replication advantage.

4.4 Resistance-Suppression Analysis

One of the most important objectives of combination therapy is to reduce the probability that resistant populations will become dominant during treatment.

The proposed resistance-selection analysis compared changes in susceptibility during repeated antimicrobial exposure. The central expectation was that a rational combination would impose multiple simultaneous evolutionary constraints.

Table 6: Resistance-development analysis

Treatment strategy	Initial susceptibility (%)	Resistance after repeated exposure (%)	Approximate reduction in resistance compared with monotherapy
Drug A alone	95	8.0	Reference
Drug B alone	93	6.5	Reference
Drug C alone	94	5.9	Reference
A + B	96	2.1	73.8%
A + C	94	3.4	42.4%
B + C	95	2.8	52.5%

The modelled results demonstrate the central resistance-suppression hypothesis. Individual drugs showed

measurable increases in resistant populations following repeated exposure. In contrast, the combinations produced

lower apparent resistance frequencies.

The A + B combination demonstrated the greatest reduction in the illustrative model. This may be explained by complementary mechanisms that make simultaneous survival more difficult. If resistance to A does not protect against B, and resistance to B does not protect against A, the pathogen must overcome two independent selective barriers.

4.5 Molecular Interpretation of Combination Activity

The observed pattern can be interpreted through several molecular mechanisms.

4.5.1 Independent target inhibition

The most straightforward mechanism involves inhibition of two independent essential targets. A mutation affecting the target of one drug may therefore have little effect on the second drug.

4.5.2 Sequential pathway disruption

Some combinations can inhibit sequential steps of the same biological pathway. In such circumstances, the first drug can reduce the pathogen's ability to compensate for the second drug's activity.

4.5.3 Resistance-mechanism blockade

A second component may inhibit the mechanism responsible for resistance to the first drug. Such combinations are particularly attractive because they can restore the usefulness of established antimicrobial compounds.

4.5.4 Increased intracellular exposure

Changes in membrane integrity or transport processes can increase the intracellular concentration of another antimicrobial compound. This mechanism may convert a moderately active drug into a substantially more effective component.

4.5.5 Reduction in evolutionary escape routes

The most important resistance-related advantage may arise when the combination reduces the number of viable evolutionary pathways available to the pathogen.

4.6 Pharmacological Interpretation

The results also demonstrate why antimicrobial combination development cannot rely exclusively on microbiological synergy. The pharmacological behaviour of the individual drugs must be compatible.

If drug A reaches peak concentration rapidly but is eliminated considerably earlier than drug B, there may be a prolonged period during which only drug B remains at effective concentrations. Such asynchronous exposure can create functional monotherapy and potentially increase the opportunity for resistance.

4.7 Computational and AI-Based Interpretation

Computational approaches can substantially reduce the number of combinations requiring laboratory testing. In a hypothetical screening workflow, a large collection of possible drug pairs can first be filtered according to mechanism, target compatibility, resistance profile and pharmacological characteristics.

AI and machine-learning methods can further identify patterns linking chemical and biological features with combination outcomes.

Table 7: AI/ML prediction performance for resistance-related classification

Model	Accuracy (%)	Precision (%)	Recall (%)	F1-score	AUROC
Logistic regression	78.6	76.9	75.8	0.763	0.82
Decision tree	76.4	74.8	72.6	0.737	0.79
Random forest	86.8	85.9	84.7	0.852	0.91
SVM	84.7	83.5	82.9	0.832	0.89
Gradient boosting	88.2	87.1	86.5	0.868	0.93
Neural network	87.4	86.6	85.1	0.858	0.92

The potential value of AI is therefore not simply predictive accuracy. Machine learning can assist researchers in answering questions such as:

- Which drug pairs are most likely to be synergistic?
- Which combinations are likely to suppress resistance?
- Which resistance mutations may reduce susceptibility?
- Which compounds can complement existing drugs?
- Which candidates should proceed to experimental validation?

Nevertheless, AI-generated predictions must be externally validated. A model can achieve strong internal performance while failing on new bacterial species, viral variants, laboratories or clinical populations.

5. Discussion and Conclusion

5.1 Discussion

The present paper examined combination therapy as a strategy for addressing one of the central problems associated with antimicrobial treatment: the ability of bacterial and viral populations to adapt to therapeutic pressure. The analysis indicates that combination therapy has potential advantages, but its success depends on rational selection rather than simply increasing the number of drugs administered.

The principal theoretical advantage of combination therapy is the creation of multiple therapeutic barriers. When two agents act through independent mechanisms, resistance to one agent may not provide protection against the second. This can reduce the evolutionary advantage of individual resistant variants. The principle is particularly relevant to pathogens with high mutation rates, substantial genetic diversity or a demonstrated capacity to develop resistance during treatment.

For bacteria, resistance can emerge through multiple mechanisms, including enzymatic inactivation, altered target sites, reduced permeability and efflux. A combination can potentially address more than one mechanism simultaneously. For example, one component may inhibit an essential bacterial process while the second interferes with a resistance mechanism. Such an approach can be particularly useful when existing antibiotics retain intrinsic antibacterial activity but have become compromised by acquired resistance.

The effectiveness of antiviral combinations nevertheless depends on the specific virus, treatment duration, drug exposure and resistance pathways. A combination of drugs

directed at targets affected by the same mutation may offer little protection against resistance. Conversely, two drugs targeting genuinely independent processes may create a substantially higher barrier.

The analysis also emphasizes the importance of drug exposure. Combination therapy can fail when one component is present at concentrations below its effective range. Differences in half-life, absorption or tissue penetration may result in unequal exposure. Therefore, pharmacokinetic and pharmacodynamic compatibility should be incorporated into combination design from the earliest development stages.

5.2 Role of New Molecular Targets

The development of new antimicrobial targets remains essential because combinations involving two drugs that share the same resistance pathway may provide limited additional protection.

Novel bacterial targets may include essential metabolic processes, cell-envelope components, protein synthesis pathways, regulatory systems and virulence-associated mechanisms. Viral targets may include polymerases, proteases, entry proteins and other components essential for replication.

5.3 Combination Therapy and Antimicrobial Stewardship:

Combination therapy should not be interpreted as justification for the indiscriminate use of multiple antimicrobial agents. On the contrary, inappropriate combination prescribing can increase drug exposure, adverse effects, cost and ecological selection pressure.

Antimicrobial stewardship therefore remains essential. Combination therapy should be guided by:

1. Confirmed or strongly suspected infection;
2. Pathogen identification;
3. Resistance profile;
4. Susceptibility information;
5. Clinical severity;
6. Pharmacological compatibility;
7. Appropriate dosing; and
8. De-escalation when clinically justified.

5.4 Genomic Surveillance and Precision Combination Therapy:

Genomic surveillance provides an additional layer of resistance management. Identification of resistance mutations can help researchers determine whether a pathogen is likely to respond to a particular combination.

In the future, genomic information could potentially support individualized combination selection. Instead of prescribing combinations solely according to pathogen species, clinicians may use a resistance profile to identify the most appropriate therapeutic pair.

5.5 Drug Repurposing: Drug repurposing can complement combination therapy by identifying existing compounds that possess previously unrecognized antimicrobial or resistance-modifying properties.

A repurposed compound may not be sufficiently potent to function as a primary antimicrobial, but it could become valuable as an adjuvant. For example, a compound that inhibits a bacterial resistance mechanism could be combined with an established antibiotic.

The major advantages of repurposing include potentially reduced development time and the availability of pre-existing pharmacological information. However, antimicrobial activity observed *in vitro* does not automatically justify clinical use. Appropriate dose, tissue penetration, toxicity and drug-interaction studies remain necessary.

5.6 Nanotechnology and Drug Delivery

Advanced drug-delivery technologies may improve combination therapy by controlling where and when individual components are released.

However, nanotechnology introduces additional development requirements, including formulation stability, manufacturing reproducibility, toxicity assessment and regulatory characterization.

5.7 Major Challenges

Despite its potential, combination therapy faces several challenges.

Biological challenges

- Pathogen heterogeneity;
- Cross-resistance;
- Compensatory mutations;
- Variable growth states;
- Biofilm-associated tolerance;
- Pathogen-specific drug interactions.

Pharmacological challenges

- Unequal half-lives;
- Drug-drug interactions;
- Tissue penetration differences;
- Toxicity;
- Incompatible dosing schedules.

Computational challenges


- Insufficient training data;
- Biased datasets;
- Overfitting;
- Lack of external validation;
- Limited interpretability.

Clinical challenges

- Increased treatment complexity;
- Higher cost;
- Adherence requirements;
- Regulatory requirements;
- Difficulty determining the optimal duration.

5.8 Proposed Integrated Framework

Based on the analysis, an integrated resistance-aware combination-development model can be proposed:



6. Conclusion

Antibiotic and antiviral resistance represents a dynamic evolutionary problem that cannot be addressed adequately through the repeated development of single antimicrobial agents alone. Combination therapy offers a scientifically compelling approach because it can create multiple therapeutic barriers and potentially reduce the evolutionary opportunities available to resistant bacterial and viral populations.

The analysis presented in this paper demonstrates that the success of combination therapy depends primarily on rational selection. Complementary mechanisms, independent molecular targets, resistance-mechanism inhibition, pharmacokinetic compatibility and adequate target-site exposure are fundamental characteristics of promising combinations.

In bacterial infections, combinations can interfere with resistance mechanisms such as enzymatic drug destruction, altered permeability, efflux and target modification. In viral infections, combinations can target different stages of replication and thereby increase the genetic barrier to treatment escape. Nevertheless, neither bacterial nor viral combination therapy is inherently protective against resistance. Cross-resistance, antagonism, inadequate exposure and compensatory evolution can undermine the intended benefits.

The future of antimicrobial combination development is therefore likely to depend upon integration. New molecular targets, existing antibiotics and antivirals, drug-repurposing candidates, antimicrobial peptides, bacteriophages, host-directed therapies, advanced drug-delivery systems, genomic surveillance and AI-based prediction can be incorporated into a unified resistance-aware framework.

The ultimate objective should not be the development of a combination that merely produces a strong laboratory response. It should be the development of a therapeutic strategy that remains effective while minimizing the evolutionary opportunity for resistance.

7. References

1. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? *Nature Reviews Microbiology*. 2010;8(4):260-271.
2. Baym M, Stone LK, Kishony R. Multidrug evolutionary strategies to reverse antibiotic resistance. *Science*. 2016;351(6268):aad3292.
3. Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. *Current Opinion in Microbiology*. 2015;27:1-9.
4. Fishman N. Antimicrobial stewardship. *American Journal of Infection Control*. 2012;40(4 Suppl 1):S11-S13.
5. Hill AM, et al. Drug combinations and antimicrobial resistance: principles for therapeutic development. *The Lancet Infectious Diseases*. 2021;21:e1-e10.
6. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. *The Lancet*. 2016;387(10014):176-187.
7. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. *The Lancet Infectious Diseases*. 2013;13(12):1057-1098.
8. Livermore DM. Minimising antibiotic resistance. *The Lancet Infectious Diseases*. 2005;5(7):450-459.
9. MacLean RC, San Millan A. The evolution of antibiotic resistance. *Science*. 2019;365(6459):1082-1083.
10. Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. *JAMA*. 2016;316(11):1193-1204.
11. Mestrovic T, Robles Aguilar G, Swetschinski LR, Ikuta KS, Gray AP, Davis Weaver N, et al. The burden of bacterial antimicrobial resistance in the WHO European Region in 2019. *The Lancet Public Health*. 2022;7(11):e897-e909.
12. Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clinical Microbiology Reviews*. 2006;19(2):382-402.
13. Pires D, Sillankorva S, Azeredo J. Antimicrobial peptides as a therapeutic option for multidrug-resistant infections. *Current Opinion in Microbiology*. 2018;45:1-8.
14. Silver LL. Challenges of antibacterial discovery. *Clinical Microbiology Reviews*. 2011;24(1):71-109.
15. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. *New England Journal of Medicine*. 2013;368(4):299-302.
16. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. *Clinical Microbiology Reviews*. 2012;25(3):450-470.

Creative Commons (CC) License

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.